Pardes Biosciences IncNASDAQ PRDS Stock Report

Pardes Biosciences, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Carlsbad, California. The company went IPO on 2021-02-17. The firm is focused on discovering, developing and commercializing therapeutics to improve the lives of patients suffering from life-threatening diseases. Its lead candidate, PBI-0451, is in clinical development and is developed to treat and prevent coronaviral (CoV) infections. The company has built a discovery platform designed to target reactive nucleophiles. The firm by leveraging its knowledge of structure-based drug design, reversible covalent chemistry and viral biology, has discovered and is developing product candidates with low nanomolar potency against SARS-CoV-2 and activity against all known pathogenic human coronaviruses. The firm's lead product candidate, PBI-0451, inhibits the main coronaviral cysteine protease, or Mpro, a viral protein essential for replication of all known coronaviruses, including SARS-CoV-2. The PBI-0451 product candidate is in Phase I clinical development.